companydata.dkcompanydata.dk

Antag Therapeutics ApS: Financial statements 2018

CVR: 38402056

Source: annual report 2018, Danish Business Authority

01/01/2018 – 31/12/2018

Antag Therapeutics ApS (CVR 38402056) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -3,123,509 and a net result of DKK -4,429,240 compared with DKK -3,901,871 the year before. Equity in the 2018 report amounted to DKK 11,816,389. The solvency ratio was 92.9%. The company had 4 employees in the financial year.

Gross Profit
DKK -3,123,509
Profit/Loss
DKK -4,429,240
Equity
DKK 11,816,389
Total Assets
DKK 12,713,696
Employees
4

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018--3.1 mio.-4.4 mio.11.8 mio.4
2017--3.7 mio.-3.9 mio.8.7 mio.2

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

Philip Just Larsen joins the board of Antag Therapeutics ApSSep 28, 2018

As of September 28, 2018, Philip Just Larsen has joined the board of directors of Antag Therapeutics ApS.

Antag Therapeutics ApS publishes interim reportJun 8, 2018

Antag Therapeutics ApS has published its interim report for the period February 8, 2017 – December 31, 2017.

About Antag Therapeutics ApS

Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 9 employees (2026). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.

Source: annual report 2025, Danish Business Authority